Updated:
Alpha Tau Medical
Alpha Tau Medical formed in 2016, emerging from the Tel Aviv University physics labs where founders Yona Keisari and Itzhak Kelson spent decades...
Alpha Tau Medical
Alpha Tau Medical formed in 2016, emerging from the Tel Aviv University physics labs where founders Yona Keisari and Itzhak Kelson spent decades researching alpha-radiation's cancer-killing properties. Uzi Sofer, a veteran of Israeli tech exits, joined as CEO to translate the academic work into a commercial enterprise. The company incorporated in Israel, later expanding its corporate footprint with U.S. headquarters in Massachusetts to run its pivotal FDA trial program. Alpha Tau deploys capital into clinical trials for its single lead asset, the Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy). The intratumoral seeds bypass conventional radiation's scatter problem — alpha particles travel no more than a few cell-widths, destroying the tumor from the inside. The company is pursuing indications in skin cancer (basal cell, squamous cell, melanoma), head and neck cancers, breast cancer, pancreatic cancer, and glioblastoma. In 2023, the firm announced an IDE nod from the FDA for a pivotal study in recurrent cutaneous squamous cell carcinoma (per the firm's regulatory filings, 2023), while its Japanese partner, J-MICC, secured approval for a multicenter liver cancer trial. Alpha Tau operates clinical sites across Israel, the United States, Japan, Italy, and Canada, reflecting a deliberately multi-jurisdictional regulatory strategy. Alpha Tau's team size remains modest relative to oncology peers, a function of its outsourced manufacturing model — seed production and delivery logistics are handled through contract partners, while the core R&D stays in-house. The company raised over $100 million in private financing before its 2022 de-SPAC merger with Healthcare Capital Corp., which brought it onto Nasdaq under the ticker DRTS (per the firm's SEC filings, 2022). Adjacent vehicles and philanthropic foundations are not disclosed. In October 2023, the firm presented real-world early-access data from its liver metastases program at the ASTRO annual meeting, demonstrating feasibility and an emerging safety profile across multiple tumor types (per ASTRO abstracts, October 2023). Alpha Tau's structural distinction lies in its procedure-economics model. The Alpha DaRT acts as a disposable medical device — inserted via a standard biopsy needle in an outpatient visit — rather than a capital-intensive machine. This positions it for adoption in community oncology settings, not just academic medical centers, and aligns with a single-use razor-and-blade revenue model that a traditional radiation oncology equipment company cannot replicate.
General information
Firm type
Asset Manager
Year founded
2016
AUM
Undisclosed
Location
Region
Middle East
Country
Israel
City
Jerusalem
Corporate office
Jerusalem, Israel
Additional offices
Boston, MA, United States · Tokyo, Japan
Principals
Uzi Sofer
Chief Executive Officer
Raphi Levy
Chief Financial Officer
Sector focus
Frequently asked questions
How does Alpha Tau's Alpha DaRT technology differ from conventional external-beam radiation?
The Alpha DaRT seeds emit alpha particles that travel only a few cell widths, delivering extremely high-energy DNA damage to the tumor while causing almost no off-target injury to surrounding healthy tissue. Conventional external-beam radiation, by contrast, uses lower-energy photons that scatter broadly and require fractionation over many sessions to manage toxicity. Alpha Tau's device is inserted once in a short outpatient procedure and does not require a linear accelerator or radiation bunker.
Is Alpha Tau Medical a pre-revenue company?
Yes. As of early 2024, Alpha Tau had no approved product generating commercial sales. Revenue has been predominantly non-recurring and related to research grants or limited compassionate-use fees. The company has stated that its primary revenue pathway will be per-seed product sales once regulatory approvals are secured in the U.S., Japan, or EU — a model akin to a disposable medical device rather than a capital-equipment sale.
Which specific cancer indications is Alpha Tau targeting first?
The lead registration programs target recurrent cutaneous squamous cell carcinoma in the United States, under an FDA-approved IDE pivotal study. Concurrent clinical work is ongoing in locally advanced pancreatic cancer, recurrent glioblastoma, and mucosal head and neck cancers. The company's Japanese partner, J-MICC, is conducting a multicenter study in liver cancers including hepatocellular carcinoma and metastases from colorectal primaries (per the firm's clinical trial registration, 2023).
Who runs investment decisions at Alpha Tau Medical?
Alpha Tau is a publicly traded Nasdaq company, so major capital allocation decisions fall to the CEO, Uzi Sofer, and the board of directors, operating under standard Israeli and U.S. public-company corporate governance. CFO Raphi Levy is responsible for treasury operations and financing execution, including the 2022 de-SPAC transaction that funded the company's pivotal clinical programs.
What is Alpha Tau's manufacturing and supply-chain model?
The company sources the raw radium-224 and manufactures the Alpha DaRT seeds through a combination of in-house production and contracted external partners. This asset-light model avoids the capital expenditures associated with building large-scale radiation facilities, but introduces a dependency on a thin supply chain for the radionuclide. Alpha Tau has maintained that its supplier network is sufficient to support its planned clinical and early-commercial volumes.
How is Alpha Tau Medical related to Tel Aviv University?
The underlying alpha-radiation technology was invented by professors Yona Keisari and Itzhak Kelson in the Tel Aviv University physics department. The university holds an equity stake through its technology transfer office, Ramot, and Alpha Tau maintains a research affiliation. The founding scientists remain scientific advisors rather than day-to-day executives.
What is Alpha Tau's regulatory strategy across jurisdictions?
The company is pursuing a multi-center clinical approach designed to support both FDA premarket approval in the U.S. and CE marking in Europe. Japan represents a parallel priority through the J-MICC partnership, capitalizing on Japan's Sakigake fast-track designation pathway for innovative medical devices. This triangulation is meant to de-risk reliance on any single regulatory body's timeline.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: